Healthcare is ripe for a change with data availability and new data analysis techniques, including the rise of AI and machine learning. As companies look to work with healthcare “data owners” to innovate and improve patient care, they need to ensure no compromises are made with patient data in the face of new threats and vulnerabilities.
TripleBlind’s recently announced strategic partnership with BC Platforms is a prime example of how our next-generation data privacy technology enables companies to safely provide and consume sensitive data without compromising privacy or security. TripleBlind’s tools will empower BC Platforms, a global leader in providing robust data for personalized medicine, to ensure data always remains encrypted throughout the process with no decryption possible, which is better than the current gold standard of homomorphic encryption or secure computing. BC Platforms’ global genomic and clinical database network of customers and data provider partners from the E.U., U.S., and Asia will leverage TripleBlind’s fastest and most secure privacy framework.TripleBlind’s ability to operate on any type of data such as images, text, voice, video, tabular data and genomic and perform any data operations, including training, AI algorithms, along with digital rights management, will give confidence to all parties involved in the transaction. This type of flexibility and scalability will allow for rapid innovation among BC Platforms’ collaborators to improve the quality of care and reduce cost. Interoperability across organizations using different hardware and cloud providers has been a significant obstacle in broader collaboration among companies and institutes worldwide. Also, data privacy regulations like GDPR, CCPA, HIPAA and data residency laws that change with location add complexity to partner with others and limit innovation at a global scale. Companies like BC Platforms can now use TripleBlind technology without worrying about interoperability issues and at the same time comply with not only GDPR, CCPA, HIPAA but also stricter regulation of data residency.
Enormous data availability has changed the way institutes operate and leverage data in any industry, but healthcare remains the one with the most potential and the most complexities. It is important to acknowledge no matter the potential of the data to improve human life, it is also important to acknowledge that organizations must create an environment which is secure, trusted and scalable for data sharing. As we work with companies like BC Platforms and other players in the provider, payer, pharma, and medical devices markets, we are hopeful about the future where healthcare innovation can happen while preserving and respecting patient privacy.
About BC Platforms
BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging the latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which provides genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms’ vision is to build the world’s leading analytics platform for healthcare and industry, providing access to diverse genomic and clinical data and samples from more than 5 million subjects, consolidated from a global network of Data Partners.
Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, and industry partners. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and presence in London, Boston and in Singapore.
About the Author
Gaurav Satam, VP, Corporate Development, has more than 13 years of experience working in the healthcare industry. Prior to joining TripleBlind, he worked for Mayo Clinic Ventures, Inovalon, a healthcare data analytics company and St. Jude in the Medical, where he worked in corporate venture, strategic development, finance, R&D, and product management roles.